Asymmetric dimethylarginine-a determinant of the effect of the high dose Simvastatin

Clinical Biochemistry

Volumn 43, Issue 10-11, 2010, Pages 843-850

  Vladimirova Kitova, Lyudmila G ^a   Deneva Koycheva, Tania ^a  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Apolipoprotein; Asymmetric dimethylarginine; Flow mediated vasodilatation; Hypercholesterolemia; Low density lipoprotein; Nitric oxide; Nitric oxide synthase; Pleiotropic effect; Statins; Total homocysteine

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; SIMVASTATIN; ARGININE; DIMETHYLARGININE;

ADULT; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ARTERY BLOOD FLOW; ARTICLE; ATHEROGENESIS; BLOOD FLOWMETRY; CHOLESTEROL BLOOD LEVEL; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PLEIOTROPY; PRIORITY JOURNAL; TREATMENT DURATION; VASODILATATION; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; MIDDLE AGED;

ADULT; ARGININE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SIMVASTATIN; VASODILATION;

EID: 77955705037     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.04.054     Document Type: Article

References (64)

1. Böger R.H., Vallance P., Cooke J.P. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atherosclerosis 2003, 4(Suppl.4):1-3.
2. Böger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006, 38:126-136.
3. Cooke J.P. ADMA:its role in vascular disease. Vasc Med 2005, 10:S11-S17.
4. Jiang J., Jiang D., Tang Y., Li N., Deng H., Li Y. Effect of simvastatin on endothelium-dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 2004, 25:893-901.
5. Kielstein J.T., Donnerstag F., Gasper S., et al. ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in Humans. Stroke 2006, 37:2024-2029.
6. Böger R.H., Sydow K., Borlak J., et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells. Circ Res 2000, 87:99-105.
7. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99:3092-3095.
8. Böger R.H., Cooke J.P., Vallance P. ADMA: an emerging cardiovascular risk factor. Vasc Med 2005, 10(Suppl 1):S1-S2.
9. Böger R.H. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003, 41:1467-1472.
10. Böger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006, 38:126-136.
11. Wang J., Sim A.S., Wang X.L., Salonikas C., Naidoo D., Wilcken D.E.L. Relation between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary artery disease. Atherosclerosis 2006, 184:383-388.
12. Ardigo D., Stuehlinger M., Franzini L., et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk European. J Clin Invest 2007, 37:263-269.
13. Juonala M., Viikari J., Alfthan G., et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young finns study. Circulation 2007, 116:1367-1373.
14. Laufs U., La F., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
15. Bolayirli I.M., Aslan M., Balci H., Altug T., Hacibekiroglu M., Seven A. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 2007, 81:121-127.
16. Eid H.M., Eritsland J., Larsen J., Arnesen H., Seljeflot I. Increased levels of asymmetric dimethylarginine in population at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003, 166:279-284.
17. Jiang J., Jiang D., Tang Y., Li N., Deng H., Li Y. Effect of simvastatin on endothelium dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 2004, 25:893-901.
18. Päivä H., Laakso J., Lehtimäki T., Isomustajärvi M., Ruoko I., Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003, 41:219-222.
19. Sasaki S., Kuwahara N., Kunitomo K., et al. Effects of Atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution and remnants lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002, 89:386-389.
20. Santili F., Bucciarelli L., Noto D., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins. Free Radic Biol Med 2007, 43:1255-1262.
21. Periera E.C., Bertolami M.C., Faludi A.A., Salem M., Bersch D., Abdalla D. Effects of Simvastatin and L-arginine on Vasodilation, Nitric Oxide Metabolites and Endogenous NOS Inhibitors in Hypercholesterolemic Subjects. Free Radic Res 2003, 37:529-536.
22. Lu T.M., Ding Y.A., Leu H.B. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004, 94:157-161.
23. Beckman J.A., Liao J.K., Hurley S., Garret L.A., Chui D., Mitra D., et al. Atorvastatin restores endothelial function in normocholetserolemic smokers independent of changes in lowdensity lipoprotein. Circ Res 2004, 95:217-223.
24. Dupuis J., Tardif J.C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999, 99:3227-3233.
25. Economodes P.A., Casselli A., Tiani E., Khaodhiar L., Horton E.S., Veves A. The effects of atorvastatin on endothelial function in diabetes patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004, 89:740-747.
26. Jörvisalo M.J., Toikka J.O., Vasankari T., Mikkola J., Viikari J., Hartiala J., et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999, 147:237-242.
27. Mullen M.J., Wright D., Donald A.E., Thorne S., Thomson H., Deanfield J.E. Atorvastatin but not L-Arginine improves endothelial function in type diabetes mellitus: A doubleblind study. J Am Coll Cardiol 2000, 36:410-416.
28. Simons L.A., Sullivan D., Simons J., Celermajer D.S. Effects of atorvastatin monotherapy and simvastatin plus cholesteramine on arterial endothelial function in patients with severe primary hypercholesterolemia. Atherosclerosis 1998, 137:197-203.
29. Vogel R.A., Correti M.C., Plotnick G.D. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996, 77:37-40.
30. van Haelst P.L., van Doormaal J.J., Asselbergs F.W., van Roon A.M., Veeger N.J., Henneman M.M., et al. Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolemia. Clin Sci 2003, 104:627-632.
31. Sheu W.H., Juang B.L., Chen Y.T., Lee W.J. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetes patients with hypercholesterolemia. Diabetes Care 1999, 22:1224-1225.
32. Van Venrooij F.V., Van de Ree M.A., Bots M.L., Stolk R.P., Huisman M.V., Banga J.D. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes. Diabetes Care 2002, 25:1211-1216.
33. Jongh S., Lilien M.R., Roods J., Stroes E., Bakker H.D., Kastelein J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002, 40:2117-2121.
34. Janatuinen T., Laakso J., Laaksonen R., Nuutila P., Lehtimaki T., Raitakari O.T., et al. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc Med 2003, 8:185-189.
35. Böger G.I., Rudolf T.K., Renke M., Schwedhelm E., Dumbadze E., Bieren A., et al. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilatation by Simvastatin. J Am Coll Cardiol 2007, 49:2274-2282.
36. Angelova E., Minkova G., Tsvetkova T. Total plasma homocysteine in bulgarian population measured by high-performance liquid chromatography with fluorescent detection-comparison with fluorescence polarization immunoassay. Clin Lab 2006, 52:527-533.
37. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery. J Am Coll Cardiol 2002, 39:257-265.
38. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adulst at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
39. Mehta J.L. Statins: understanding clinical use 2004, Saunders, Phyladelphia, PA, USA.
40. Bates K., Ruggeroli C.E., Goldman S., Gaballa M.A. Simvastatin restores endothelial NO mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol 2002, 283:H768-H775.
41. Wilson S.H., Simari R.D., Best P.J., et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001, 21:122-128.
42. Guven G.S., Atalar E., Yavuz B., Beyazit Y., Kekilli M., Kilicarslan A., et al. Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholesterolemia. J Natl Med Assoc 2006, 98:627-630.
43. Böger R.H. Asymmetric dimethylarginine (ADMA) modulates endothelial function therapeutic implications. Vasc Med 2003, 8:149-151.
44. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99:3092-3095.
45. Lüftjohann D., Sigit J.I., Locatelli S., Bergmann K. Letter to the editor: high-dose simvastatin (80mg/day) decreases plasma concentrations of total homocysteine in patients with hypercholesterolemia. Atherosclerosis 2001, 155:265-266.
46. Jankowski P., Kawecka-Jaszcz K. Letter to the editor: lipid-lowering drugs and homocysteine a comparison between statins and other lipid-lowering drugs. Atherosclerosis 2004, 172:191-194.
47. Miltiadous G., Papakostas J. Letter to the editor: statins and homocysteine. Atherosclerosis 2003, 166:199-200.
48. Ivashchenko C.Y., Bradley B.T., Ao Z., Leiper J., Vallance P., Douglas J.G. Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the response element dinding proteins, SREBP1c and -2. Am J Physiol Heart Circ Physiol 2010, 298:H251-H258.
49. Oguz A., Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008, 49:303-311.
50. Jang J.J., Ho H.K., Kwan H.H., Fajardo L.F., Cooke J.P. Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine. Circulation 2000, 102:1414-1419.
51. Böger G.I., Maas R., Schwedhelm E., Bierend A., Benndorf R., Kastner M., et al. Improvement of endothelium-dependent vasodilation by simvastatin is potentiated by combination with l-arginine in patients with elevated asymmetric dimethylarginine levels. J Am Coll Cardiol 2004, 43:525A. (Suppl.).
52. Vladimirova-Kitova L.G., Deneva T., Angelova E., Nikolov F., Marinov B., Mateva N. Relationship of asymmetric dimethylarginine with flow-mediated dilation in subjects with newly detected severe hypercholesterolemia. Clin Physiol Funct Imaging 2008, 28:417-425.
53. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylagrinine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998, 98:1842-1847.
54. Vladimirova-Kitova L., Terzieva D., Marinov B. Intima-media thickness and flow mediated vasodilation in asymptomatic subjects with newly detected severe hypercholesterolemia. Echocardiography 2009, 26(9):1060-1068.
55. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton V.P., Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004, 291:2821-2827.
56. Kajinami K., Takekoshia N., Brousseau M.E., Schaefer E.J. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004, 177:219-234.
57. Lefer A.M., Campbell B., Shin Y.K., et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999, 100:178-184.
58. Lefer D.J., Scalia R., Jones S.P., et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 2001, 15:1454-1456.
59. Yamada M., Huang Z., Dalkara T., et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by l-arginine after chronic statin treatment. J Cereb Blood Flow Metab 2000, 20:709-717.
60. Kano H., Hayashi T., Sumi D., et al. A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA. Biochem Biophys Res Commun 1999, 259:414-419.
61. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998, 101:2711-2719.
62. Favre A., Monpere C., Voyer C., et al. How to improve primary prevention in asymptomatic high risk subjects. Eur Heart J 2004, 6:J59-J63. Suppl J.
63. Schuster H. Under-treated high risk patients: identifying patients in high-risk subgroup and treating them to LDL targets. Eur Heart J 2005, 7:20-28. Suppl A.
64. Landmesser U., Hornig B., Drexler H. Endothelial dysfunction in hypercholesterolemia-mechanisms, pathophysiological importance and therapeutic interventions. Semin Thromb Hemost 2000, 26:529-537.